Fresenius Kabi

Bad Homburg, Germany
Biologics (Sterile Injectables) Monoclonal Antibody Biosimilars Small Molecule API HPAPI / Oncology Injectables mRNA Cell Therapy (equipment/processing platform) Sterile Fill-Finish Compounding (outsourcing facility)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (7) ○ EMA GMP ○ MHRA GMP

Quick Facts: Fresenius Kabi

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Bad Homburg, Germany
Modalities
Biologics (Sterile Injectables), Monoclonal Antibody, Biosimilars, Small Molecule API, HPAPI / Oncology Injectables, mRNA, Cell Therapy (equipment/processing platform), Sterile Fill-Finish, Compounding (outsourcing facility)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Fresenius Kabi

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesBiologics (Sterile Injectables), Monoclonal Antibody, Biosimilars, Small Molecule API, HPAPI / Oncology Injectables, mRNA, Cell Therapy (equipment/processing platform), Sterile Fill-Finish, Compounding (outsourcing facility)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (9 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press7 articles
Broad modality coverage (9 modalities)

Recent News 7 articles

news Wed, 21 Ja
Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing - Indian Pharma Post
Source →
news Wed, 14 Ja
Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement - Business Wire
Source →
news Wed, 14 Ja
Faster to the bedside: Collaboration in cell therapy of Fresenius Kabi and TQ Therapeutics - European Biotechnology Magazine
Source →
news Thu, 28 Au
Fresenius debuts European consortium to pursue bedside CAR-T production - Fierce Pharma
Source →
news Thu, 22 Ja
Cellular Origins, Fresenius Kabi Tout Automation Milestone in Scaling CGT Manufacturing - Contract Pharma
Source →
news Thu, 17 Oc
Fresenius Kabi and Cellular Origins link for CGT manufacture - Pharmaceutical Technology
Source →
news Fri, 23 Ja
Milestone Reached in Cell and Gene Therapy Robotic Automation and Manufacturing Collaboration - Genetic Engineering and Biotechnology News
Source →

Frequently Asked Questions About Fresenius Kabi

What is Fresenius Kabi's CDMO Signal Score?
Fresenius Kabi has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Fresenius Kabi for a manufacturing program?
Use the free AI matchmaker to compare Fresenius Kabi against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics (Sterile Injectables) CDMOs → HPAPI / Oncology Injectables CDMOs → mRNA CDMOs → Cell Therapy (equipment/processing platform) CDMOs →

Similar CDMOs

BioCina
Adelaide, Australia
Biologics (Microbial), Plasmid DNA, mRNA, LNP, Sterile Fill-Finish, Recombinant Proteins, Vaccines, Biosimilars, High Potency/Oncology Injectables, Blow-Fill-Seal
Mabion S.A.
Konstantynów Łódźki, Poland
Monoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
Kemwell Biopharma
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish
Kemwell Biopharma, Bangalore
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish, Lyophilized Drug Product
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics